V. Deshmukh

发表

A regenerative approach to the treatment of multiple sclerosis

F. Gage, P. Schultz, Krishnan Padmanabhan, 2013, Nature.

A Small-Molecule Inhibitor of the Wnt Pathway, Lorecivivint (SM04690), as a Potential Disease-Modifying Agent for the Treatment of Degenerative Disc Disease.

J. Hood, Y. Yazici, M. Ibanez, 2020, The spine journal : official journal of the North American Spine Society.

Small molecule mediated proliferation of primary retinal pigment epithelial cells.

Matthew S. Tremblay, P. Schultz, B. Lu, 2013, ACS chemical biology.

Recruiting cytotoxic T cells to folate-receptor-positive cancer cells.

Ying Sun, P. Schultz, Vaughn V. Smider, 2013, Angewandte Chemie.

FRI0552 Sm04690, a wnt pathway inhibitor: anti-inflammatory and cartilage protective effects in preclinical oa models

C. Swearingen, Y. Yazici, V. Deshmukh, 2018, Osteoarthritis.

SM04755, a small‐molecule inhibitor of the Wnt pathway, as a potential topical treatment for tendinopathy

J. Hood, C. Barroga, Y. Yazici, 2020, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.

B. Melchior, Ch Lai, J. Hood, 2019, Osteoarthritis and cartilage.

A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee.

J. Hood, C. Barroga, M. Ibanez, 2018, Osteoarthritis and cartilage.

The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models.

S. Cha, C. Mak, C. Barroga, 2020, Cancer letters.

SAT 0604 AUTOLOGOUS BLOOD AND CORTICOSTEROID LOCAL INJECTION IN TREATMENT OF PLANTAR FASCIITIS ( RANDOMIZED , CONTROLLED MULTICENTER CLINICAL TRIAL )

Y. Yazici, B. Hofilena, M. Ibanez, 2022 .

Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia.

Peter G Schultz, Chan Hyuk Kim, P. Schultz, 2014, Angewandte Chemie.

An immunosuppressive antibody-drug conjugate.

Yu Cao, Feng Wang, Peter G Schultz, 2015, Journal of the American Chemical Society.

A CXCR4-targeted site-specific antibody-drug conjugate.

Ying Sun, P. Schultz, Feng Tian, 2014, Angewandte Chemie.

Small-molecule inducer of β cell proliferation identified by high-throughput screening.

Matthew S. Tremblay, P. Schultz, P. McNamara, 2013, Journal of the American Chemical Society.

Discovery of a small molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying treatment for knee osteoarthritis

J. Hood, Y. Hu, C. Barroga, 2016 .

Anti-inflammatory Properties of SM04690, a Small Molecule Inhibitor of the Wnt Pathway as a Potential Treatment for Knee Osteoarthritis

C. Barroga, Y. Yazici, M. Ibanez, 2017 .

OP0069 Discovery of A Small Molecule Inhibitor of The WNT Pathway (SM04690) as A Potential Disease Modifying Treatment for Knee Osteoarthritis

Y. Hu, V. Deshmukh, J. Hood, 2016 .

Experimental tendinopathy treatment with SM04755, a topical small molecule inhibitor of the WNT pathway

Y. Yazici, B. Hofilena, L. Dellamary, 2018 .

A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee.

C. Barroga, M. Ibanez, B. Tam, 2018, Osteoarthritis and cartilage.

An immunosuppressive antibody-drug conjugate.

Matthew S. Tremblay, Chan Hyuk Kim, P. Schultz, 2015, Journal of the American Chemical Society.

AB0070 LORECIVIVINT (SM04690), A POTENTIAL DISEASE-MODIFYING TREATMENT FOR KNEE OSTEOARTHRITIS, DEMONSTRATED CARTILAGE-PROTECTIVE EFFECTS ON HUMAN OSTEOARTHRITIC EXPLANTS

D. D’Lima, W. Bugbee, S. Grogan, 2020, Annals of the Rheumatic Diseases.